Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study

Teppei Hagino; Hidehisa Saeki; Eita Fujimoto; Naoko Kanda

doi:10.1093/ced/llae410

Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study

Clin Exp Dermatol. 2024 Oct 8:llae410. doi: 10.1093/ced/llae410. Online ahead of print.

Authors

Teppei Hagino¹, Hidehisa Saeki², Eita Fujimoto³, Naoko Kanda¹

Affiliations

¹ Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
² Department of Dermatology, Nippon Medical School, Tokyo, Japan.
³ Fujimoto Dermatology Clinic, Funabashi, Japan.

PMID: 39378322
DOI: 10.1093/ced/llae410

Abstract

Background: Upadacitinib, a janus kinase 1 (JAK1) inhibitor, is effective for moderate-to-severe atopic dermatitis (AD). Upadacitinib treatment may be discontinued in some patients, however, the effectiveness and safety of retreatment after its withdrawal have not been precisely examined in real-world practice.

Objectives: To evaluate the effectiveness and safety of upadacitinib retreatment after withdrawal in real-world clinical practice for Japanese AD patients.

Methods: This retrospective study included 62 Japanese patients with moderate-to-severe AD treated with upadacitinib 15 mg (n = 38) or 30 mg (n = 24). Effectiveness was assessed using eczema area severity index (EASI) and peak pruritus numerical rating scale (PP-NRS) before treatment (baseline), at time-periods of discontinuation, retreatment, and week 12 after retreatment of upadacitinib. Safety was evaluated through the incidence of treatment-emergent adverse events (TEAE).

Results: EASI and PP-NRS scores significantly decreased at week 12 after retreatment of upadacitinib compared to baseline in both 15 mg and 30 mg groups. Achievement rates of EASI 75, EASI 90, and EASI 100 at week 12 after retreatment were 83.8%, 56.8%, and 18.9% in 15 mg group, and 87.0%, 56.5%, and 17.4% in 30 mg group, respectively. TEAEs were mild or moderate, and no serious adverse events or deaths were reported.

Conclusions: Retreatment of upadacitinib after withdrawal effectively improved clinical signs and pruritus in patients with AD, with a manageable safety profile, supporting its use for long-term management of AD.

Keywords: JAK; atopic dermatitis; retreatment; upadacitinib; withdrawal.

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.